Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Jake Shortt et al.|Blood|2018Cited by 8
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle StudyDavid T Yeung, On Behalf of the ALLG, Naranie Shanmuganathan et al.|Blood|2019Cited by 7